IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$9.29 USD
-0.20 (-2.11%)
Updated May 16, 2024 04:00 PM ET
After-Market: $9.29 0.00 (0.00%) 6:22 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IGMS 9.29 -0.20(-2.11%)
Will IGMS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IGMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IGMS
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
IGMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for IGMS
Bank of America Securities Sticks to Their Hold Rating for IGM Biosciences (IGMS)
IGM Biosciences (IGMS) Gets a Buy from Truist Financial
Short Report: Wayfair bears scrambling as pre-earnings build-up is foiled
IGM Biosciences: Unlikely To Move The Needle Again In 2024
IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns with EPS Projections Amidst Clinical ...